Cellectis shares are trading higher after the company announced that the FDA granted Regenerative Medicine Advanced Therapy designation to lasmecabtagene timgedleucel

Cellectis Q2 Adj. EPS $(0.19) Beats $(0.27) Estimate, Sales $6.904M Miss $13.225M Estimate

Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.27) by 29.63 percent. This is a 13.64 percent increase over losses of $(0.22) per share from the

Cellectis Presents Lasme-cel Phase 1 Data Showing Manageable Safety Profile With CRS Grade 3 In 4% Of Patients And Eti-cel Achieving 63% Complete Response In r/r B-NHL

Cellectis Secures FDA Regenerative Medicine Advanced Therapy Designation For lasme-cel, CD22-Targeting Allogeneic CAR-T Cell Therapy Product Candidate, For Treatment Of r/r B-ALL

Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug